Form 4: Carolyn Starrett Acquires NEOGENOMICS INC Shares

Carolyn S. Starrett, a Director at NEOGENOMICS INC, reported the acquisition of stock options and restricted stock units on June 23, 2026.

Summary

• Carolyn S. Starrett, a Director of NEOGENOMICS INC, acquired securities on June 23, 2026.
• The acquired securities include stock options to purchase 9,784 shares of common stock at an exercise price of $11.20, with an expiration date of June 1, 2036.
• Additionally, 14,125 restricted stock units were acquired, which vest on June 1, 2027.
• These securities are directly beneficially owned by Ms. Starrett.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as a director acquiring equity-based compensation suggests confidence in future stock performance.

Positives

• Director Carolyn S. Starrett has acquired a significant number of stock options and restricted stock units, indicating confidence in the company's future.
• The acquisition of 9,784 stock options at a strike price of $11.20 suggests a belief that the stock price will exceed this level.
• The acquisition of 14,125 restricted stock units, vesting in June 2027, aligns management incentives with long-term shareholder value.

Future Outlook

The acquisition of stock options and restricted stock units by a director suggests a positive outlook on the company's future performance, as these instruments are typically acquired with the expectation of stock price appreciation.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as potential indicators of management's confidence in the company's prospects within the biotechnology and diagnostics sector.

Stakeholder Impact

• Shareholders may view this as a positive signal of insider confidence in the company's future growth and stock value.
• Employees may be encouraged by the alignment of director incentives with long-term company success.

Next Steps

• Vesting of restricted stock units on June 1, 2027.
• Potential exercise of stock options before their expiration on June 1, 2036.

Key Dates

Recommendation

This filing reports an insider acquisition of stock options and restricted stock units, which is generally a positive signal. However, it does not contain operational or financial results that would warrant a strong buy or sell recommendation. Therefore, a 'hold' is appropriate pending further financial disclosures.

Keywords

NEOGENOMICS INC, NEO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Carolyn S. Starrett